RET, ret proto-oncogene, 5979

N. diseases: 607; N. variants: 162
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 GeneticVariation disease BEFREE 58% PTCs presented a genetic alteration either RET/PTC rearrangement, BRAF V599E mutation or both: three cases of PTCs (25%) presented a RET/PTC rearrangement; three cases of PTCs (25%) presented a BRAF V599E mutation and in one case (8%) both alterations were identified. 15859312 2005
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 Biomarker disease BEFREE Papillary thyroid carcinomas in humans are associated with the ret/PTC oncogene and, following loss of p53 function, may progress to anaplastic carcinomas. 10934169 2000
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 GeneticVariation disease BEFREE PTC with RET/PTC rearrangement as well as the TPC-1 cell line (the only one harboring RET/PTC rearrangement) did not show the BRAF(V599E) mutation. 12881714 2003
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 GeneticVariation disease BEFREE Papillary thyroid carcinomas are associated with nonoverlapping activating mutations of RET, NTRK, RAS and BRAF, which altogether are present in approximately 70% of cases. 16551863 2006
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 GeneticVariation disease BEFREE PTC is associated with gene rearrangements generating RET/PTC and TRK oncogenes, and to the BRAFV600E activating point mutation. 21339735 2011
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 GeneticVariation disease BEFREE Papillary thyroid carcinoma (PTC) generally shows an excellent prognosis except in cases with aggressive backgrounds or clinicopathological features. 29349484 2018
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 GeneticVariation disease BEFREE Papillary thyroid carcinoma (PTC) and medullary thyroid carcinoma (MTC) are characterized by genomic rearrangements and point mutations in the proto-oncogene RET. 29436694 2018
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 GeneticVariation disease BEFREE RET mutations cause several human diseases such as papillary thyroid carcinoma, multiple endocrine neoplasia types 2A and 2B, and Hirschsprung's disease. 11544105 2001
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 Biomarker disease BEFREE Ret gene transcripts and protein were found in all PTC variants as well as in their corresponding metastases. 11579677 2001
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 Biomarker disease BEFREE RET was rearranged in 52% of microcarcinomas, a statistically significant higher frequency than that found previously in clinically evident PTCs using the same technique. 11742034 2001
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 GeneticVariation disease BEFREE RET is also found mutated in sporadic medullary thyroid cancer (MTC) and rearranged in sporadic papillary thyroid carcinomas. 11746981 2001
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 Biomarker disease BEFREE RET/PTC rearrangements are believed to be tumor-initiating events in papillary thyroid carcinomas. 14555660 2003
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 AlteredExpression disease BEFREE RET oncogene expression of papillary thyroid carcinoma in Korea. 15170542 2004
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 Biomarker disease BEFREE RET is the oncogene that causes papillary thyroid carcinoma and medullary thyroid carcinoma. 15331579 2004
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 GeneticVariation disease BEFREE RET/PTC is a transforming sequence created by the fusion of the tyrosine kinase domain of the RET protooncogene with the 5' end of the locus D10S170 designated by probe H4 and is frequently found activated in human papillary thyroid carcinomas. 1542652 1992
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 Biomarker disease BEFREE RET/PTC1 and RET/PTC3 are the markers for papillary thyroid carcinoma. 15502856 2004
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 Biomarker disease BEFREE RET/PTC expression and BRAF mutations were mutually exclusive. 16402937 2006
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 GeneticVariation disease BEFREE RET rearrangements in post-Chernobyl papillary thyroid carcinomas with a short latency analysed by interphase FISH. 16641909 2006
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 Biomarker disease BEFREE RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. 17210721 2007
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 Biomarker disease BEFREE RET-associated PTC tumors are phenotypically indolent and relatively less aggressive than RET-related MTCs. 19487296 2009
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 Biomarker disease BEFREE RET/PTC, Ras, and receptor tyrosine kinase could dually activate the PI3K/Akt and MAPK pathways. 20578891 2010
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 Biomarker disease BEFREE Rearranged during transfection (RET)/papillary thyroid carcinoma (PTC) gene rearrangements are one of the major genetic alterations found in papillary thyroid carcinoma. 24957039 2014
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 Biomarker disease BEFREE Rearranged during transfection (RET)/papillary thyroid carcinoma gene rearrangements, BRAF (B-RAF proto-oncogene, serine/threonine kinase) gene mutations, RAS (rat sarcoma) mutations, and vascular endothelial growth factor receptor 2 angiogenesis pathways are some of the known pathways playing a crucial role in the development of thyroid cancer. 25789503 2015
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 Biomarker disease BEFREE RET/PTC rearrangement is the most common genetic modification identified in this category of cancer, increasing proliferation and dedifferentiation by the activation of the RET/PTC-RAS-BRAF-MAPK-ERK signaling pathway. 27314338 2016
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.600 Biomarker disease BEFREE RET is activated, as RET/PTC oncogene, by somatic rearrangements which link the TK domain to a constitutive dimerization interface in papillary thyroid carcinomas. 8570194 1995